And from this article on Yahoo it is seen that when we get the first good results that this news will quickly expand through patient and physician associations.

It is particularly interesting to me that Leronlimab will hopefully be approved for another indication, but no one will be able to prevent its use off-label if the results are good.

Lerolimab can become very popular quickly for metastatic cancer, and the drug will be approved for another indication, this will be an interesting situation for CYDY.

I believe that there are such examples that the drug becomes very popular and sought before approval for certain indications, maybe someone knows better.